Physician profile
Mark A Rodriguez
NPI 1982708111
$18,864.47
in general payments reported to CMS, 2019-2025
61 companies · $2,818 in 2025
The $2,818 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,626 · 2020: $2,430 · 2021: $2,058 · 2022: $2,049 · 2023: $2,954 · 2024: $2,931 · 2025: $2,818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,626 · Education: $76.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,625.72 |
| Education | $76.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,489.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $2,040.74 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,880.92 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Bayer Healthcare Pharmaceuticals INC. | $1,361.12 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,332.50 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $1,282.66 | 2019-2025 | |
| Allergan, INC. | $903.35 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $857.99 | 2019-2023 | Trintellix |
| Amarin Pharma, INC. | $552.72 | 2019-2023 | |
| Axsome Therapeutics, INC. | $509.27 | 2023-2025 | Symbravo, Sunosi, Auvelity |
| Glaxosmithkline, LLC. | $455.22 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $446.79 | 2021-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $418.35 | 2019-2025 | Synjardy, Jardiance, Ofev |
| Antares Pharma, INC. | $283.95 | 2020-2024 | Xyosted, Tlando, Nocdurna |
| Merck Sharp & Dohme LLC | $280.46 | 2019-2023 | Dificid |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.